Cytotoxicity and Regulatory Compliance

by Raoni

In the pharmaceutical and biomedical sectors, cytotoxicity assessment is a fundamental requirement in preclinical development programs and in the qualification of materials, devices and active substances. Major international guidelines — including ICH M3(R2), ICH S7A/B, ISO 10993-5, as well as EMA and FDA recommendations — recognize in vitro assays as the first step in biological safety evaluation.

Today, cytotoxicity testing is a crucial tool for supporting go/no-go decisions, identifying the most promising candidates, and minimizing the risk of failure during advanced development stages. Within a GxP framework, it also plays a pivotal role in process validation, quality control, and demonstrating regulatory compliance.

Recent methodological advances have led to increasing standardization of protocols, with emphasis on robustness, reproducibility, and data traceability. The integration with document management and data integrity systems ensures the reliability of results from from both regulatory and audit perspectives.

In this context, cytotoxicity assays are no longer viewed simply as preliminary screening tools, but as strategic assets that support regulatory submissions, risk assessment and ultimately patient safety.


Case Study: Cytotoxicity Assay on Hepatocytes

The Challenge

During the development of a novel anti-inflammatory compound, the client required an early-stage cytotoxicity evaluation on hepatic cell lines in order to support informed decision-making during preclinical development.

Our Approach

We combined cell viability assays with advanced multiparametric analyses, investigating dose-dependent effects on:

  • mitochondrial function
  • oxidative stress

The Result

Early identification of the compound’s toxic profile enabled a targeted reformulation strategy, significantly improving the project’s likelihood of success.


XTT Assay

The XTT assay is based on the reduction of tetrazolium salt into soluble formazan by mitochondrial dehydrogenases. It allows for a quantitative, reproducible, and, if necessary, high-throughput assessment of cell viability, while maintaining excellent compatibility with automated workflows.


Baffo’s Column: “Biological Evaluation of Medical Devices” by Boutrand

Biological Evaluation of Medical Devices by Boutrand is considered a key reference for professionals involved in the biological and toxicological assessment of medical devices. The book explores the practical application of ISO 10993 standards, with particular emphasis on the regulatory interpretation of cytotoxicity testing.


Did you know?

According to ISO 10993-5, a material is considered cytotoxic when cell viability is reduced by more than 30% compared to the control. This quantitative criterion is frequently scrutinized during audits and technical dossier reviews.

You may also like